Gwenaëlle Maradan

Discipline

Economies et finances (5)

Type de document

Articles (10)

Co-auteur

Date

Source

Mot-clé

Treatment (6) enquête (5) santé (5) World health (5) Science (5) Health (5) Use (5) Health (5) analyse (4) Care (4) Symptoms (4) Social sciences (4) Persons (4) Patients (4) Medical care (4) Manufacturers' agents (4) Human beings (4) French (4) Finance (4) Evidence (4) Commission merchants (4) Anxiety (4) Finance (4) Analysis (4) Patients (4) Models (4) stress (3) information (3) effet (3) âge (3)

Documents écrit par Gwenaëlle Maradan (10) | parle de Gwenaëlle Maradan (0)

Screening for tobacco and cannabis use by general practitioners: a French nationwide representative survey
Tangui Barré et al. (26 avr. 2024)
Gender and Drug Use Discrimination Among People Who Inject Drugs: An Intersectional Approach Using the COSINUS Cohort
Ilhame Anwar et al. (12 mars 2024)
Acceptability of and attitudes to the therapeutic use of cannabis and cannabidiol in people with Parkinson’s disease: A French survey
Tangui Barré et al. (2024)
Improvements in Patient-Reported Outcomes Following Initiation of Dolutegravir-Based or Low-Dose Efavirenz-Based First-Line Antiretroviral Therapy: A Four-Year Longitudinal Analysis in Cameroon (NAMSAL ANRS 12313 Trial)
Marwân Bousmah et al. (1 nov. 2023)
A novel community‐based therapeutic education program for reducing alcohol‐related harms and stigma in people with alcohol use disorders: A quasi‐experimental study ( ETHER study)
Tangui Barré et al.
Hepatitis B in Senegal: A Successful Infant Vaccination Program but Urgent Need to Scale Up Screening and Treatment (ANRS 12356 AmBASS survey)
Lauren Périères et al.
Sibling status, home birth, tattoos and stitches are risk factors for chronic hepatitis B virus infection in Senegalese children: A cross‐sectional survey
Lauren Périères et al.
Hepatitis B Vaccination in Senegalese Children: Coverage, Timeliness, and Sociodemographic Determinants of Non-Adherence to Immunisation Schedules (ANRS 12356 AmBASS Survey)
Lauren Périères et al.
Cost-utility analysis of a dolutegravir-based versus low-dose efavirenz-based regimen for the initial treatment of HIV-infected patients in Cameroon (NAMSAL ANRS 12313 trial)
Marwân Bousmah et al. (1 mars 2021)
Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial)
Marwân-Al-Qays Bousmah et al. (2021)